

# 1 **Diverging the anthracycline class of anti-cancer drugs for** 2 **superior survival of acute myeloid leukemia patients**

3  
4 Xiaohang Qiao,<sup>1,2,\*†</sup> Sabina Y. van der Zanden,<sup>3,\*</sup> Xiaoyang Li,<sup>4,\*</sup> Minkang Tan,<sup>3</sup> Yunxiang  
5 Zhang,<sup>4</sup> Ji-Ying Song,<sup>6</sup> Merle A. van Gelder,<sup>3</sup> Feija L. Hamoen,<sup>3</sup> Lennert Janssen,<sup>3</sup> Charlotte  
6 L. Zuur,<sup>1,2</sup> Baoxu Pang,<sup>3</sup> Olaf van Tellingen,<sup>5</sup> Junmin Li,<sup>4,†</sup> and Jacques Neefjes<sup>3,†</sup>

7  
8 <sup>1</sup>Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;

9 <sup>2</sup>Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute, Amsterdam, The  
10 Netherlands;

11 <sup>3</sup>Department of Cell and Chemical Biology, ONCODE Institute, Leiden University Medical Center, Leiden, The  
12 Netherlands;

13 <sup>4</sup>Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for  
14 Translational Medicine, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine,  
15 Shanghai, China;

16 <sup>5</sup>Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;

17 <sup>6</sup>Division of Experimental Animal Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;

18 \*These authors contributed equally to this work.

19

20 †Correspondence: email: x.qiao@nki.nl; drlijunmin@126.com; j.j.c.neefjes@lumc.nl

21

## 22 **Key words:**

23 Anthracycline, Doxorubicin, Aclarubicin, Acute Myeloid Leukemia, Cardiotoxicity, Histone

24 Eviction, Bio-distribution, Cross-resistance

## 25 **Abstract**

26 The efficacy of anthracycline-based chemotherapeutics, which include doxorubicin and its  
27 structural relatives daunorubicin and idarubicin, remains almost unmatched in oncology,  
28 despite a side effect profile including cumulative dose-dependent cardiotoxicity, therapy-  
29 related malignancies and infertility. Detoxification of anthracyclines while preserving their  
30 anti-neoplastic effects is arguably a major unmet need in modern oncology, as cardiovascular  
31 complications that limit anti-cancer treatment are now a leading cause of morbidity and  
32 mortality among the 17 million cancer survivors in the U.S.. To address this, we examined  
33 different clinically relevant anthracycline drugs with respect to a series of features including  
34 mode of action (chromatin and DNA damage), bio-distribution, anti-tumor efficacy and  
35 cardiotoxicity in pre-clinical models and patients. We show that different anthracycline drugs  
36 have surprisingly individual efficacy and toxicity profiles. In particular, aclarubicin stands  
37 out in pre-clinical models and clinical trials as it potently kills cancer cells, does not induce  
38 therapy-related malignancies or cardiotoxicity, and can be safely administered even after a  
39 maximum cumulative dose of either ida- or doxorubicin has been reached. Retrospective  
40 analysis of aclarubicin used in second-line treatment of relapsed/refractory AML patients  
41 showed similar survival effects to its use in first line, leading to an almost 25% increase in 5-  
42 year overall survival. Considering individual anthracyclines as different drugs provides new  
43 treatment options that strongly improve survival of cancer patients while limiting the toxic  
44 side-effects.

45

## 46 **Introduction**

47 Most anthracyclines function as poisons of the enzyme topoisomerase II (TopoII) that trap it  
48 on chromatin and thus induce DNA double-strand breaks (DSBs) [1]. In addition, these drugs  
49 also evict histones from defined genomic areas, which results in delayed DNA damage repair

50 and epigenetic and transcriptomic alterations, collectively termed chromatin damage [2-4].  
51 Histone eviction appears to be a major cytotoxic activity of anthracyclines [5]. TopoII  
52 poisons, like etoposide, that only generate DSBs are considerably less effective in cancer  
53 treatment [2, 6], and also less toxic [5, 7]. On the contrary, aclarubicin only induces histone  
54 eviction and is highly effective in treating *de novo* acute myeloid leukemia (AML) [5].  
55 Hence, DNA damage appears not to be a prerequisite for effective anti-cancer activities.  
56 Removing DNA damage from chromatin damage activity mitigates cardiotoxicity and  
57 therapy-related tumorigenesis of anthracyclines, without hampering their anti-cancer effect  
58 [5]. Clinical application of detoxified anthracyclines will confer major benefits in cancer  
59 therapy, expanding treatment options for patients with comorbidities including older adults  
60 [8] and reducing late effects, particularly for pediatric patients [9]. Detoxified anthracyclines  
61 would enable chronic treatment of cancer, while the current toxic anthracyclines only allow  
62 for limited treatment due to cumulative dose-dependent cardiotoxicity risk. Here, we  
63 systematically evaluated anthracycline drugs currently used in clinic against a series of key  
64 features to determine whether they differ in terms of anti-neoplastic potency, site of action  
65 and toxicity profiles. We identified aclarubicin, currently used only in Asia for AML patients  
66 with high comorbidity indices, as an anthracycline variant that lacks cardiotoxicity side  
67 effects and can be used after maximum dose of doxo- or ida in mice and men. Aclarubicin-  
68 based therapy increases the overall survival of relapsed/refractory AML patients by almost  
69 25%. These data illustrate how aclarubicin can transform leukemia treatment for children,  
70 unfit adults and relapsed/refractory AML patients that currently have a poor prognosis,  
71 addressing a major unmet need in current oncology practice.

72

## 73 **Materials and methods**

### 74 **Reagents**

75 Doxorubicin and etoposide were purchased from Pharmachemie (The Netherlands),  
76 daunorubicin was obtained from Sanofi-Aventis and epirubicin was obtained from Accord  
77 Healthcare Limited (UK), idarubicin was obtained from Pfizer and Santa Cruz Biotechnology  
78 (sc-204774). Aclarubicin for in vivo mouse experiments was obtained from Shenzhen Main  
79 Luck Pharmaceuticals Inc. Aclarubicin (for in vitro experiments, sc-200160) and amrubicin  
80 (sc-207289) were obtained from Santa Cruz Biotechnology.

81

## 82 **Cell culture**

83 K562, MM6, MOLM13, MV4:11, and U937 and THP-1 were cultured in RPMI-1640  
84 medium supplemented with 8% fetal calf serum (FCS). OCI-AML2 and OCI-AML3 and  
85 OCI-AML4 were cultured in Iscove's Modified Dulbecco's medium (IMDM) supplemented  
86 with 8% FCS and glutamine. MelJuSo cells were maintained in IMDM supplemented with  
87 8% FCS. All cell lines were maintained in a humidified atmosphere of 5% CO<sub>2</sub> at 37 °C,  
88 regularly tested for the absence of mycoplasma and STR profile identified.

89

## 90 **Cell line construction**

91 For endogenous tagged GFP-H2B K562 cells, mScarlet was swapped for GFP in the  
92 homology repair construct using NheI and BglIII and cells were generated as described [5].  
93 Co-transfection into K562 cells was done by electroporation using Lonza SF cell line kit.  
94 ABCB1 overexpressing K562 cells were generated as described [10]. Endogenous tagged  
95 3×Flag-TopoII $\alpha$  K562 cell line was generated using HR-3×Flag construct designed at least 40  
96 base pairs up and downstream of the genomic TopoII $\alpha$  stop codon. The gRNA target  
97 sequence was designed using the ZANG Lab CRISPR tool (<http://crispr.mit.edu/>) and cloned  
98 into the pX330 vector. Primers used for the HR construct: 5'-  
99 CACCGATGATCTGTTTTAAAATGTG-3' and 5'-AAACCACATTTTAAAACAGATC

100 ATC-3'. Co-transfection of ssDNA oligo and CRISPR plasmid (pX459) into K562 cells was  
101 performed by electroporation using Lonza SF cell line kit. Primers used for genotyping:  
102 forward primer: 5'-TAAGCAGAATTCATGCCACTTATTTGGGCAAT-3' and reverse  
103 primer: 5'-TGCTTAAAGCTTTGCCCATGAGATGGTCACTA-3'.

104

### 105 **DNA damage assessed by Western blot and CFGE**

106 After 2-hour drug treatment of indicated drugs at 5 $\mu$ M, cells were washed with PBS. WB and  
107 CFGE were performed as described [11]. Images were quantified with ImageJ.

108

### 109 **Fractionation assay**

110 Endogenously tagged GFP-H2B cells ( $1 \times 10^6$ ) were pre-incubated with protease inhibitor  
111 cocktail (P1860-1ML, Sigma-Aldrich) for 1 hour followed by 3-hour treatment with 10  $\mu$ M  
112 of the indicated drugs. Cells were dissolved in lysis buffer (50mM Tris-HCl pH 8.0, 150 mM  
113 NaCl, 5 mM MgCl<sub>2</sub>, 0.5% NP40, 2.5% glycerol supplemented with protease inhibitors, 10  
114 mM NMM) for 5 min on ice, and then centrifuged for 10 min at 15,000 g at 4°C. Both  
115 nucleus (pellet) and cytosol (supernatant) were washed once and submitted for Western Blot  
116 analysis. Primary antibodies used for detection: GFP (1:1000) [12], Lamin B1 (1:1000,  
117 12987-I-AP, Proteintech), Calnexin (1:1000, C5C9, Cell signaling).

118

### 119 **Time-lapse confocal microscopy**

120 For time-lapse confocal imaging, MelJuSo cells were seeded in 35-mm bottom petri dish  
121 (Poly-dlysin Coated, MatTek Corporation), transfected with TopoII $\alpha$ -GFP construct  
122 (effectene, Qiagen) and imaged upon treatment with the indicated drugs [2]. Leica SP8  
123 confocal microscope system, 63 $\times$ lens, equipped with a climate chamber was used. TopoII $\alpha$ -  
124 GFP distribution was quantified using Leica Application Suite X software.

125

### 126 **Short-term cell viability assay**

127 Twenty-four hours after seeding into 96-well plates, cells were treated with indicated drugs  
128 for 2 hours at physiologically relevant concentrations [2]. Subsequently, drugs were removed  
129 by extensive washing, and cells were cultured for an additional 72 hours. Cell viability was  
130 measured using the CellTiter-Blue viability assay (Promega). Survival was normalized to the  
131 untreated control samples after correction for the background signal.

132

### 133 **ChIP-seq**

134 Endogenous tagged 3 $\times$ Flag-TopoII $\alpha$  K562 cells were treated with 10  $\mu$ M of indicated drugs  
135 for 4 hours. Cells were fixed and processed as described [3, 13]. ChIP was done with anti-  
136 Flag M2 (F3165, Sigma), followed by sequencing on an Illumina HiSeq2000 platform  
137 (Genome Sequencing Service Center of Stanford Center for Genomics and Personalized  
138 Medicine Sequencing Center).

139 ChIP-seq data were processed identically using the ENCODE Data Coordination Center  
140 (DCC) ChIP-seq pipeline (<https://github.com/ENCODE-DCC/chip-seq-pipeline2>) (v1.9.0).  
141 Briefly, the ChIP-seq reads were aligned to the human reference genome (GRCh37/hg19)  
142 using Bowtie2 [14]. Duplicate reads were removed using Picard MarkDuplicates  
143 (RRID:SCR\_006525). Peaks of each sample were called against the whole-cell lysates  
144 replicates using SPP [15] with the parameters '-npeak 300000 -speak 155 -fdr 0.01'. The

145 blacklisted regions described by ENCODE were discarded [16]. Reproducible peaks were  
146 intersected from two biological replicates and annotated with epigenomic signatures of K562,  
147 downloaded from the Roadmap Epigenomics Project [17]. Normalized TopoII $\alpha$  binding  
148 affinity matrix: consensus peaks by samples, principle component analysis and differential  
149 binding affinity analysis were performed using the R package DiffBind [18].

150

## 151 **ATAC-seq**

152 K562 cells were treated with 10  $\mu$ M of indicated drugs for 4 hours. Cells were fixed and  
153 processed as described [19, 20]. DNA was processed using a customized library preparation  
154 method for ATAC-seq and was sequenced using an Illumina HiSeq4000 platform.

155 ATAC-seq data were processed identically using the ENCODE Data Coordination Center  
156 (DCC) ATAC-seq pipeline (<https://github.com/ENCODE-DCC/atac-seq-pipeline>) (v1.10.0).  
157 Briefly, the ATAC-seq reads were aligned to the human reference genome (GRCh37/hg19)  
158 using Bowtie2 [14]. Duplicate reads were removed using Picard MarkDuplicates  
159 (RRID:SCR\_006525). Peaks were called using MACS2 [21] with the setting of ‘-p 0.01 --  
160 shift -75 --extsize 150 --nomodel -B --SPMR --keep-dup all’, then followed by blacklisted  
161 regions filtering described by ENCODE [16]. Reproducible peaks were identified from two  
162 biological replicates and annotated with epigenomic signatures of K562, downloaded from  
163 the Roadmap Epigenomics Project [17]. ATAC-seq signal tracks for all the samples were  
164 generated by bedtools with the command ‘bedtools genomecov -scale’ using the read count  
165 per million (CPM) normalization and convert to bigwig files using bedGraphToBigWig.  
166 Normalized ATAC-seq read density matrix: consensus peaks by samples, principle  
167 component analysis and differential chromatin accessibility analysis were performed using  
168 the R package DiffBind [18].

169

## 170 **The bio-distribution of anthracyclines in mice**

171 FVB/NRj mice ordered from Janvier Labs (Le Genest-Saint-Isle, France) were housed in  
172 individually ventilated cages under specific pathogen-free conditions in the animal facility of  
173 the NKI (Amsterdam, The Netherlands). All mouse experiments were approved by the  
174 Animal Ethics Committee of the NKI and were performed according to institutional and  
175 national guidelines. Male mice (8-week old) were i.v. injected with Doxo, Acla, Amr, Epi or  
176 Ida at 5 mg/kg ( $n = 5$  per group). Four hours post injection, animals were sacrificed, and  
177 plasma, heart, lung, liver, kidney, spleen, brain, thymus, axillary and inguinal lymph nodes,  
178 and testis+epididymis were collected. Hearts were cut into two pieces with coronal section.  
179 One piece was fixed in EAF fixative (ethanol/acetic acid/formaldehyde/saline, 40:5:10:45  
180 v/v/v/v) and processed for Phospho-H2AX (Ser139) IHC (1:100, #2577, Cell Signaling). The  
181 other half of the heart and the rest of organs were weighted, frozen and analyzed by LC-  
182 MS/MS [5].

183

## 184 **The cardiotoxicity of anthracyclines in mice**

185 FVB/NRj mice (10–11-week old) were i.v. injected with 5 mg/kg of Doxo, 5 mg/kg of Acla,  
186 or 5 ml/kg of saline every 2 weeks for 4 times. After 4-week interval, the animals were i.v.  
187 injected with 5 mg/kg of indicated drug or 5 ml/kg of saline every 2 weeks for another 4  
188 times. The mice were monitored every other day. When body weight loss was more than  
189 20%, or circulation failure occurred, animal was euthanized by CO<sub>2</sub>. Subsequently, full body  
190 anatomy was performed. All organs were collected, fixed in EAF fixative and embedded in  
191 paraffin. Sections were cut at 2 μm from the paraffin blocks and stained with hematoxylin  
192 and eosin, and 4 μm for immunohistochemistry of Desmin (1:200, M0760,  
193 DakoCytomation), Vimentin (1:100, #5741, Cell Signaling), or Periostin (1:100, ab215199,  
194 Abcam). Pathology slides were reviewed twice by an expert mouse pathologist who was



195 blind to the treatment. Incidence rate (IR = [number of mice with the specific side effect over  
196 a time period]/[sum of mice × time at risk during the same time period]) and cumulative  
197 incidence (CI = [number of mice with specific side effect at end time point]/[total number of  
198 mice at start]) were calculated for indicated side effects.

199

## 200 **r/rAML patients**

201 Patients with refractory or relapse AML treated between July 2012 and July 2022 at Ruijin  
202 hospital, China were enrolled in this retrospective study. Some patients participated in trail  
203 ChiCTR-OPC-14005712, ChiCTR-OPC-15006896, ChiCTR-IIR-16008809, ChiCTR-OIC-  
204 16008952, ChiCTR-IIR-16008962 and ChiCTR-IIR-17011677. This study was approved by  
205 the ethics committee of Ruijin Hospital, all patients provided written informed consent.  
206 Cytogenetic risk was classified according to the modified Southwest Oncology Group criteria  
207 [22], and integrated risk was classified as described [23]. The treatment details were decribed  
208 in supplemental materials and methods. The baseline characteristics and clinical outcomes of  
209 the patients are summarized in supplemental Tables 1 and 2, respectively.

210 Cytogenetic risk was classified according to the modified Southwest Oncology Group  
211 criteria [22]: (1) favorable risk, including t(8;21) and inv(16) or t(16;16)(p13;q22); (2)  
212 unfavorable risk, including del(5q) or monosomy 5, monosomy 7 or del(7q), abnormal 3q,  
213 9q, 11q, 21q, or 17p, t(6;9), t(9;22), and complex karyotypes (three or more unrelated  
214 chromosomes abnormal); and (3) intermediate risk, including normal karyotypes and all other  
215 anomalies. FLT3 internal tandem duplication and mutations in CEBPA, NPM1 and IDH1/2  
216 were tested. Integrated risk was classified as described [23]. CR was defined as bone marrow  
217 blasts <5%, absolute neutrophil count  $\geq 1 \times 10^9/L$ , and platelet count  $\geq 100 \times 10^9/L$ , and absence  
218 of extramedullary disease. Partial remission was defined as having <15% (and a 50%  
219 decrease in bone marrow blasts) but >5% blasts or with <5% blasts but not reaching the CR

220 criteria for blood cell count or clinical manifestation. The baseline characteristics and clinical  
221 outcomes of the patients are summarized in supplemental Tables 1 and 2, respectively.

222

### 223 **AML treatments**

224 CAG patients were treated with 15–25 mg/m<sup>2</sup> of Ara-C (cytarabine) injected s.c. every 12 h  
225 on days 1–4, 20 mg/d of Acla infused i.v. on days 1–4, and 200 µg/m<sup>2</sup> of granulocyte  
226 stimulating factor (G-CSF) administered s.c. daily on days 1–4. G-CSF was reduced, or  
227 temporarily stopped when neutrophilia was >5×10<sup>9</sup>/L. IA patients were treated with 6–10  
228 mg/m<sup>2</sup> of Ida infused i.v. on days 1–3 and 100–200 mg/m<sup>2</sup> of Ara-C on days 1–7. VA  
229 patients were injected with 75 mg/m<sup>2</sup> of azacitidine s.c. daily on days 1–7, and administered  
230 with venetoclax orally, once daily. The dose of venetoclax was 100 mg on day 1 and 200 mg  
231 on day 2; and 400 mg on days 3–28. In all subsequent 28-day cycles, the dose of venetoclax  
232 was initiated at 400 mg daily. The other induction chemotherapy for r/rAML patients  
233 included IA, DA, FLAG, CLAAG and CHA regimens. For patients treated with DA regimen,  
234 20 mg/m<sup>2</sup> of decitabine was administered i.v. daily on days 1–5, and 1 g/m<sup>2</sup> of Ara-C was  
235 injected every 12 hours on days 6–7. For patients treated with FLAG regimen, fludarabine  
236 was infused i.v. at 30 mg/m<sup>2</sup> on days 2–6; 4 hours after fludarabine infusion, Ara-C was  
237 injected i.v. at 1.5–2 g/m<sup>2</sup> over 3 hours on days 2–6; G-CSF was administered at 5 µg/kg s.c.  
238 on days 1–5; additional G-CSF may be administered since 7 days after the end of  
239 chemotherapy until WBC count >500/uL. For patients >60-year-old, the dose may be reduced  
240 to 20 mg/m<sup>2</sup> for fludarabine and 0.5–1 g/m<sup>2</sup> for cytarabine. For patients treated with CLAAG  
241 regimen, 5 mg/m<sup>2</sup> of cladribine was infused i.v. over 2 hours on days 1–5; 15 mg/m<sup>2</sup> of Ara-  
242 C was injected s.c. every 12 hours on days 1–10; trans retinoic acid (ATRA) was  
243 administered orally at 45 mg/m<sup>2</sup> on days 4–6, then at 15 mg/m<sup>2</sup> on days 7–20; 300 µg G-  
244 CSF was injected s.c. on day 0. For patients treated with CHA regimen, 5 mg/m<sup>2</sup> of

245 cladribine was infused i.v. over 2 hours on days 1–5; 2 mg/m<sup>2</sup> of homoharringtonine was  
246 infused i.v. over 2 hours on days 1–5; 1 g/m<sup>2</sup> of Ara-C was injected 2 hours after cladribine  
247 on days 1–5.

248

## 249 **Statistical analyses**

250 Results are shown as mean ± SEM or mean ± SD. Statistical analysis was performed using  
251 Prism unless otherwise specified. All the in vitro experiments were performed with a  
252 minimum of three independent trials with the exception of CHIP-seq and ATAC-seq which  
253 were in biological duplicates. All the animals of mouse experiments are shown in the dot  
254 plots. Statistical tests are indicated in each figure legend.

255

## 256 **Results**

### 257 **Mechanisms of action and cross-resistance of anthracyclines**

258 To assess whether the various clinically administered anthracyclines (Fig. 1A) differ in their  
259 DNA- and chromatin-damaging activities, as well as cross-resistance, we exposed AML cell  
260 line THP1 at a clinically relevant dose for 2 hours followed by further culturing to mimic the  
261 pharmacokinetics in patients [24]. DNA damage was assessed by constant-field gel  
262 electrophoresis (CFGE) [11] and phosphorylation of H2AX at Ser139 ( $\gamma$ H2AX) [25] as  
263 detected by Western blotting. Doxorubicin (Doxo), daunorubicin (Daun), epirubicin (Epi),  
264 idarubicin (Ida), and amrubicin (Amr) all induced DSBs, unlike aclarubicin (Acla) (Fig. 1B–  
265 E). Next, chromatin damage as the result of histone eviction was visualized by a fractionation  
266 assay using K562 cells with endogenously tagged GFP-H2B. Except for Amr, all the tested  
267 anthracyclines induced histone release from nucleus and accumulation in cytosol (Fig. 1F,G;  
268 Fig. S1A). Furthermore, all histone-evicting anthracyclines were able to redistribute GFP-  
269 TopoII $\alpha$  on chromatin (Fig. S1B,C). Cytotoxicity assays revealed poor anti-cancer activity

270 for the DNA-damaging analog Amr, while the other analogs bearing chromatin-damaging  
271 activity were effective in eliminating various myeloid leukemia cell lines (Fig. 1H).

272 In addition to treatment-limiting cardiotoxicity, drug resistance could also limit the effect  
273 of anthracycline drugs. ABCB1 is a major drug efflux transporter contributing to  
274 anthracycline resistance [26]. We generated a Doxo-resistant leukemia cell line by  
275 overexpressing ABCB1 [10] and tested its sensitivity to other anthracyclines (Fig. 1I–K; Fig.  
276 S1D). The ABCB1-overexpressing cells acquired resistance to Doxo, Daun, Epi and Amr, but  
277 failed to export Ida and Acla efficiently (Fig. 1J,K). These data together indicate that  
278 clinically relevant anthracyclines should be considered as distinct drugs with unique features  
279 and different efficiencies. Evicting histones and relocalizing TopoII $\alpha$  while not inducing  
280 DSBs, as in the case of Acla, apparently suffices for efficient cytotoxicity.

281

## 282 **Epigenetic selectivity of TopoII $\alpha$ redistribution and histone eviction of** 283 **anthracyclines**

284 Anthracyclines poison TopoII by disrupting its interface with DNA by their sugar moieties  
285 and the cyclohexene ring [27]. However, the anthracycline-specific redistribution of TopoII  
286 and its association with histone eviction have not been characterized. We addressed this in  
287 K562 cells whose epigenomic information has been extensively profiled by ENCODE  
288 consortium [28]. Chromatin immunoprecipitation followed by deep sequencing (ChIP-seq)  
289 against endogenously tagged TopoII $\alpha$  was performed 4 hours after anthracycline exposure in  
290 independent duplicate experiments (Fig. S2A). The resulting ChIP-seq profiles analyzed by  
291 principal component analysis (PCA) suggested that all histone-evicting anthracyclines cause  
292 extensive and drug-specific TopoII $\alpha$  redistribution as compared to untreated or Amr-treated  
293 cells (Fig. 2A,B). To characterize this drug-specific TopoII $\alpha$  redistribution, we coupled the  
294 ChIP-seq data to the epigenetic information of ENCODE (Fig. 2C). With the same sugar

295 moiety and cyclohexane (Fig. 1A), Daun and Doxo (also labeled as hydroxyDaun) depleted  
296 TopoII $\alpha$  from active chromatin regions, like DNase I hypersensitive regions (DHS),  
297 H3K4me1, H3K4me2, H3K4me3, H3K9ac, H3K27ac, H3K79me2 and H2A.Z [29]. Instead,  
298 TopoII $\alpha$  was trapped in compact chromatin regions marked by H3K27me3 [29], H3K9me1  
299 [30] and H3K9me3 [31] (Fig. 2C). Ida and Acla depleted TopoII $\alpha$  from broader chromatin  
300 states, except for H3K9me3 [31], H3K27me3 [29] and H3K36me3 [31] decorated regions  
301 (Fig. 2C). Epi, with an epimerizing hydroxyl group at the sugar moiety (Fig. 1A), further  
302 depleted TopoII $\alpha$  from H3K36me3 [31] modified regions (Fig. 2C). It is worth noting that the  
303 redistribution of TopoII $\alpha$  at regions with unknown epigenetic features was increased for all  
304 drugs, except for Amr (Fig. 2C).

305 While the TopoII $\alpha$  redistribution showed drug specificity, we continued to identify  
306 histone eviction preferences of each anthracycline using transposase-accessible chromatin  
307 with sequencing (ATAC-seq) [19] in K562 cells (Fig. 2D). In line with its lack of chromatin-  
308 damaging activity (Fig. 1F,G), Amr failed to induce *de novo* open chromatin and could  
309 therefore be found close to untreated cells in PCA plot (Fig. 2E). Similar to the TopoII $\alpha$   
310 redistribution pattern, the other tested anthracyclines evicted histones mostly from open  
311 chromatin regions, once again exhibiting distinct preferences (Fig. 2F). As histone  
312 modifications are required for recruitment of TopoII $\alpha$  to DNA [32], selective eviction of  
313 histones from open chromatin regions may contribute to the observed depletion of TopoII $\alpha$   
314 from the same regions. Based on the comparative analysis of TopoII $\alpha$  ChIP-seq and the  
315 ATAC-seq experiments, we observed that regions identified by both ATAC-seq and TopoII $\alpha$   
316 ChIP-seq were greatly decreased by histone-evicting anthracyclines (Fig. 2G,H; Fig. S2B).  
317 Nonetheless, outside of overlapping regions, TopoII $\alpha$  redistribution and *de novo* accessible  
318 chromatin were usually not associated with each other, indicating that these may constitute  
319 two independent effects of anthracyclines (Fig. S2B). Thus, integration of TopoII $\alpha$  ChIP-seq

320 and ATAC-seq revealed the connection between histone eviction and TopoII $\alpha$  depletion in  
321 transcriptionally active regions, as well as selective impact of each analog on the epigenetic  
322 landscape. Each clinically used anthracycline has individual genomic preferences, which may  
323 define drugs with different specificity.

324

### 325 **Bio-distribution of anthracyclines**

326 Acla is effective in eliminating a large variety of cancer cells in tissue culture [5]. However, it  
327 is mainly used in treating AML and is less effective against solid tumors [33, 34]. This could  
328 be the result of differences in biodistribution of anthracyclines. To test this, we performed a  
329 comprehensive pharmacokinetic study for Acla and the other clinically used anthracyclines in  
330 mice. Four hours post iv injection of a clinically relevant dose of indicated drug at 5 mg/kg  
331 [35], Doxo, Epi and Ida showed similar bio-distribution patterns across different organs (Fig.  
332 3A; Fig. S3A). Amr had a similar tissue distribution as Doxo, but showed reduced  
333 distribution to lung, kidneys, and heart. Brain tissue was poorly penetrated by all drugs (Fig.  
334 3A; Fig. S3A). A notable exception was Acla, which accumulated in lymphoid organs  
335 (spleen, thymus and lymph nodes) but poorly distributed to other organs (Fig. 3A; Fig. S3A).  
336 This might be an explanation why Acla is ineffective in treating solid tumors, as opposed to  
337 hematologic tumors.

338 We further evaluated DNA damage in the heart in response to drug exposure. While  
339 Doxo, Epi and Ida incited persistent DNA damage in the heart, the hearts of Acla- and Amr-  
340 treated mice did not show any  $\gamma$ H2AX signals 4 hours after drug administration (Fig. 3B; Fig.  
341 S3B), in line with poor tissue penetration of Acla and Amr and the fact that Acla does not  
342 induce DNA damage at all.

343

### 344 **Acla is safe and well tolerated following Doxo treatment**

345 Doxo, Daun, Ida and Epi all induce cumulative dose-dependent cardiotoxicity, which limits  
346 patient treatment to only few courses. Since Acla treatment is not associated with  
347 cardiotoxicity [5], we reasoned that it could be safe to apply this drug to mice following  
348 treatment with cardiotoxic anthracyclines. To test this, Acla was administered to mice after  
349 half-maximum cumulative dose of Doxo (Fig. 4A) and followed over time. Cardiotoxicity  
350 induced by Doxo caused cardiac hypertrophy and remodeling that presented as thrombus  
351 formation in the left atrium and auricle of the heart accompanied by inflammation, fibrosis  
352 and calcification [5, 36] (Fig. 4B; Fig. S4A). Further staining for profibrotic proteins  
353 vimentin [37] and periostin [38], and cytoskeletal protein desmin [39], revealed impairment  
354 of myocytes and fibrosis in the stroma (Fig. 4C–H; Fig. S4B–F). With impaired cardiac  
355 function, Doxo-treated mice died from circulation failure (Fig. 4I).

356 Reflecting clinical observations [40] and our prior work [5], the incidence, latency and  
357 histopathological alterations of Doxo-induced cardiotoxicity developed in a dose-dependent  
358 manner (Fig. 4A, D-C vs D-D), whereas eight courses of Acla treatment showed no  
359 abnormalities in the heart (Fig. 4F–K; Fig. S4, A-A vs C-C/D-C/D-D). More importantly,  
360 Acla treatment after half-maximum cumulative dose of Doxo did not aggravate cardiotoxicity  
361 (Fig. 4; Fig. S4, D-A vs D-D). Similarly, pre-treatment with Acla did not make mice more  
362 susceptible to Doxo-induced cardiotoxicity (Fig. 4; Fig. S4, A-D vs D-C/D-D). Hence, Acla  
363 is safe and well tolerated following Doxo treatment in this model system. Considering limited  
364 cardiotoxicity, little cross-resistance and differences in epigenomic specificities between  
365 anthracyclines, Acla would be predicted to act as an independent drug in salvage  
366 relapsed/refractory AML (r/rAML) patients who have already received the maximum  
367 cumulative dose of cardiotoxic anthracyclines. Such systematic studies have not been  
368 reported.

369

## 370 **CAG strongly improves the survival of relapsed/refractory AML patients**

371 R/rAML is one of the most challenging situations in hematology, with a 5-year overall  
372 survival (OS) of only 10% [41]. The prognosis of elderly or unfit r/rAML patients is even  
373 more disappointing [42]. Unfortunately, no specific salvage regimen has appeared as a  
374 standard treatment for r/rAML [42]. CAG regimen, containing low-dose of cytarabine, Acla  
375 and G-CSF, has been widely used in China and Japan for treating AML [43, 44]. It is well  
376 tolerated by r/r and elderly AML patients with lower toxicity than conventional  
377 chemotherapies [43-45]. To compare the efficacy of CAG to other salvage chemotherapies in  
378 r/rAML, we conducted a single-center retrospective study at Ruijin hospital (Shanghai,  
379 China).

380 A total of 186 r/rAML patients, treated between July 2012 and July 2022, were included  
381 in the study. In this group of patients, fit patients with *de novo* AML often received Ida in  
382 combination with cytarabine (IA) rather than Daun or Doxo for first-line therapy, as Ida is  
383 more effective for induction therapy in AML [46, 47]. However, all three anthracyclines are  
384 cardiotoxic [48]. Among the patients who developed refractory and relapse after primary IA  
385 treatment for *de novo* disease, 66 patients received CAG regimen (2<sup>nd</sup>-line CAG group), 67  
386 received other chemotherapy regimens (2<sup>nd</sup>-line others group), and 34 received emerging  
387 target therapy regimen venetoclax + azacitidine (2<sup>nd</sup>-line VA group) (Fig. 5A). 19 patients  
388 who were treated with CAG for both *de novo* and r/r diseases were enrolled to illustrate that  
389 Acla does not contribute to cardiotoxicity and is compatible with extended treatment  
390 (1<sup>st</sup>&2<sup>nd</sup>-line CAG group) (Fig. 5A). Notably, at Ruijin hospital, CAG is usually applied to *de*  
391 *novo* AML patients with unfit conditions who are not expected to tolerate conventional  
392 intensive chemotherapies. The demographic and clinical characteristics of all patients at  
393 r/rAML diagnosis are summarized in supplemental Table 1. There was no significant  
394 difference between 2<sup>nd</sup>-line CAG group and any other group with respect to age, gender,



395 French-American-British type, cytogenetic risk, and frequent oncogenic mutations. Slightly  
396 more patients in the 2<sup>nd</sup>-line others group were diagnosed with favorable integrated risk than  
397 in the other arms of the study.

398 The overall complete remission (CR) rate after induction was 74% for the 2<sup>nd</sup>-line CAG  
399 group, which is significantly higher than that of the 2<sup>nd</sup>-line others (37%) and the 2<sup>nd</sup>-line VA  
400 group (35%) (Table 1). Patients with favorable and intermediate cytogenetics or integrated  
401 risk responded better to CAG. However, cytogenetics or integrated risk was not prognostic  
402 for the other groups (Table 1). Among the patients with a favorable and intermediate risk, the  
403 complete remission rate of 2<sup>nd</sup>-line CAG was superior to that of 2<sup>nd</sup>-line others and the 2<sup>nd</sup>-  
404 line VA group (Table 1). While age is a poor prognostic factor for AML [42], no significant  
405 difference was seen for CAG outcome in patients <60- and ≥60-year-old. Actually, for  
406 patients ≥60-year-old, 2<sup>nd</sup>-line CAG also outperformed other treatment regimens (Table S2).  
407 No CR and major prognostic mutation associations were detected for any treatment group  
408 due to small cohort (Table S2). In terms of CR rate, compared to the 2<sup>nd</sup>-line CAG group that  
409 first received IA, the 1<sup>st</sup>&2<sup>nd</sup>-line CAG group performed slightly less optimally due to unfit  
410 conditions. However, this treatment protocol was not inferior to the 2<sup>nd</sup>-line others and the  
411 2<sup>nd</sup>-line VA group (Table 1; Table S2), suggesting that CAG remains effective and tolerable  
412 in unfit r/rAML patients, even after prior CAG treatments.

413 Since both CAG and VA therapy were well tolerated, some patients continued with these  
414 regimens for consolidation therapy and long-term maintenance. Among these were patients  
415 treated for up to 11 times with CAG without any cardiac issues, far more than other  
416 anthracyclines (Fig. S5A). This strategy was not an option for IA treatment due to  
417 accumulated cardiotoxicity and resistance. Superior CR rates and/or sustainable treatment  
418 schedule of CAG and VA translated into a more than 20% better OS as compared to 2<sup>nd</sup>-line  
419 others group (Fig. 5B,C; Fig. S5B,C). Nonetheless, event-free survival analysis indicated a

420 better durable response of 2<sup>nd</sup>-line CAG when compared to 2<sup>nd</sup>-line VA (Fig. 5D,E), possibly  
421 due to the development of VA resistance [49]. Of note, the 1<sup>st</sup>&2<sup>nd</sup>-line CAG patients were  
422 selected for the limited toxicity of this regimen due to unfit conditions, which is associated  
423 with poor prognosis. Still, these patients achieved comparable OS as the 2<sup>nd</sup>-line CAG group  
424 (Fig. 5B,C; Fig. S5D,E). Taken together, these findings reveal that CAG regimen can be a  
425 superior, low-toxicity chemotherapy for r/rAML, including those with unfit conditions.

426

## 427 **Discussion**

428 Despite their devastating side effect profiles, anthracyclines including doxorubicin,  
429 daunorubicin and idarubicin have been cornerstones of oncology treatment for over 50 years.  
430 While the molecular mechanisms of action have been mostly considered the same across  
431 different anthracycline analogs, clinical observations and our previous studies have indicated  
432 that this does not apply to all variants [2, 3, 5, 50]. Here, we performed a comprehensive  
433 analysis of clinically relevant anthracyclines against key parameters including mode of  
434 action, epigenomic selectivity and clinical performance, and find individual anthracyclines  
435 have substantially different pharmacological properties. In the course of our evaluation, Acla  
436 stood out as it is minimally cardiotoxic and prefers lymphoid organs over solid tissues.  
437 Attributing to its high therapeutic index for AML, we demonstrate that Acla can be safely  
438 used in second-line therapy after initial treatment of cardiotoxic anthracyclines, leading to  
439 23% higher 5-year OS for r/rAML patients.

440 A common feature of anthracyclines is their poisoning of TopoII $\alpha$ . TopoII $\alpha$  plays a role in  
441 all areas of chromosome structure, from nucleosome assembly and disassembly to  
442 chromosome condensation and segregation between daughter cells [51-53]. DSB induction  
443 mediated by the catalytic activity of TopoII $\alpha$  has always been considered as the primary  
444 cytotoxic mechanism of anthracyclines [1]. However, this dogma is challenged by Acla and

445 other anthracycline variants whose major cytotoxic activity is chromatin damage, also known  
446 as histone eviction [54]. It has been reported that deregulation of TopoII $\alpha$  leads to cell death  
447 in a manner independent of its catalytic activity [55, 56]. Therefore, without poisoning  
448 TopoII $\alpha$  for DNA damage, depleting and redistributing TopoII $\alpha$  are already detrimental, as  
449 illustrated by Acla. This finding further uncovers the anti-cancer mechanism of chromatin  
450 damage caused by histone eviction.

451 While Acla was first introduced into clinic 40 years ago (it was available in Europe until  
452 2004 and was never registered in the U.S.), it is surprising that the unique effects of Acla in  
453 r/rAML has never been realized. Our data suggest that applying CAG therapy in r/rAML  
454 patients would increase their 5-year OS by 23%. If Acla was incorporated into current AML  
455 regimens, 10,000 r/rAML patients in the U.S. and Europe [57] would survive annually from  
456 this off-patent and low-cost drug. The impact on pediatric oncology will be even more  
457 profound, as 50% of childhood cancer patients receive high-dose anthracyclines and go on to  
458 have 5- to 15-fold increased risk for heart failure compared to the general population [9].  
459 Introducing Acla in their treatment would mitigate this side effect. Considering old drugs in  
460 new ways may therefore substantially – and expeditiously – improve the survival and quality  
461 of life of many cancer patients, as exemplified here.

462

## 463 **Abbreviations**

Acla	Aclarubicin
AML	Acute myeloid leukemia
Amr	Amrubicin
Ara-C	Cytarabine
ATAC-seq	Assay for Transposase-Accessible Chromatin using sequencing
ATRA	Retinoic acid
CAG	cytarabine, Acla and G-CSF
CFGE	Constant-field gel electrophoresis
ChIP-seq	Chromatin immunoprecipitation followed by sequencing

CR	Complete remission
Daun	Daunorubicin
DHS	DNase I hypersensitive regions
Doxo	Doxorubicin
DSBs	DNA double-strand breaks
Epi	Epirubicin
FCS	Fetal calf serum
G-CSF	Granulocyte colony stimulating factor
GEO	Gene expression omnibus
IA	Ida in combination with cytarabine
Ida	Idarubicin
IMDM	Iscove's modified dulbecco's medium
IR	Incidence rate
OS	Overall survival
PCA	Principal component analysis
$\gamma$ H2AX	phosphorylation of H2AX at Ser139
r/rAML	relapsed/refractory AML
SDS	Sodium dodecyl sulfate
TopoII	Topoisomerase II

464

## 465 **Supplementary Information**

466 Supplementary Materials.dox includes Figures S1 to S5 and Tables S1 to S2.

467

## 468 **Declarations**

### 469 **Ethics approval and consent to participate**

470 All mouse experiments were approved by the Animal Ethics Committee of the NKI and were  
471 performed according to institutional and national guidelines. The retrospective clinical study  
472 was approved by the ethics committee of Ruijin Hospital, and all patients provided written  
473 informed consent.

474

### 475 **Availability of data and materials**

476 The sequencing data supporting the findings of this study are available at the Gene  
477 Expression Omnibus (GEO) under accession numbers GSE240443  
478 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE240443>). Source data are  
479 provided with this paper. Clinical data are available from the corresponding authors upon  
480 reasonable request and with permission of Ruijin hospital.

481

## 482 **Competing interests**

483 J.N. is a shareholder in NIHM that aims to produce Acla for clinical use. The authors do not  
484 declare any other competing interests.

485

## 486 **Funding**

487 This work was supported by grants from the European Research Council (ERC) (advanced  
488 grant ERCOPE 694307) (J.N.), Dutch Cancer Society (KWF 11356) (J.N.), Institute for  
489 Chemical Immunology from NWO Gravitation (NWO 024.002.009) (J.N.), Spinoza award  
490 funded by the Ministry of Education, Culture and Science of the Netherlands (NWO  
491 00897590) (J.N.), RIKI foundation (C.L.Z.).

492

## 493 **Authors' contribution**

494 Contribution: X.Q., S.Y.v.d.Z. and J.N. designed experiments. X.Q. and S.Y.v.d.Z.  
495 performed experiments. O.v.T., F.L.H., and M.A.v.G. contributed to experiments. Y.Z. and  
496 X.L. collected the r/rAML data. X.Q., X.L., J.L. and J.N. analyzed the clinical data. M.T. and  
497 B.P. performed and analyzed ChIP-seq and ATAC-seq experiments. L.J., Y.L. and B.P. made  
498 stable cell lines. J.S. performed pathological analyses. C.L.Z. contributed to the result  
499 interpretation. X.Q., S.Y.v.d.Z. and J.N. wrote the manuscript, with the input of all authors.  
500 All authors read and approved the final manuscript.

501

## 502 **Acknowledgements**

503 The authors thank the people from the Preclinical Intervention Unit of the Mouse Clinic for  
504 Cancer and Ageing (MCCA) at NKI for their technical support performing the animal  
505 experiments and the staff from the Experimental Animal Pathology facility at NKI for their  
506 service on histochemistry and immunochemistry staining; Prof. J.P. Vandenbroucke and M.  
507 Schaapveld for help with the epidemiological assessment of clinical data; J. Sarthy and I.  
508 Berlin for comments and critical reading of the Manuscript.

509

## 510 **References**

- 511 1. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by  
512 mammalian DNA topoisomerase II. *Science*. 1984;226(4673):466-8.
- 513 2. Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, et al. Drug-induced histone eviction from  
514 open chromatin contributes to the chemotherapeutic effects of doxorubicin. *Nature communications*.  
515 2013;4:1908.
- 516 3. Pang B, de Jong J, Qiao X, Wessels LF, Neeffjes J. Chemical profiling of the genome with anti-cancer drugs  
517 defines target specificities. *Nature chemical biology*. 2015;11(7):472-80.
- 518 4. Yang F, Kemp CJ, Henikoff S. Doxorubicin enhances nucleosome turnover around promoters. *Curr Biol*.  
519 2013;23(9):782-7.
- 520 5. Qiao X, van der Zanden SY, Wander DPA, Borrás DM, Song JY, Li X, et al. Uncoupling DNA damage  
521 from chromatin damage to detoxify doxorubicin. *Proceedings of the National Academy of Sciences of the*  
522 *United States of America*. 2020;117(26):15182-92.
- 523 6. Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell  
524 lung cancer: a stopped multicentre randomised trial. *Medical Research Council Lung Cancer Working*  
525 *Party. Lancet*. 1996;348(9027):563-6.
- 526 7. Hong WK, Nicaise C, Lawson R, Maroun JA, Comis R, Speer J, et al. Etoposide combined with  
527 cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and  
528 with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a  
529 randomized trial of the Bristol Lung Cancer Study Group. *Journal of Clinical Oncology*. 1989;7(4):450-6.
- 530 8. Sekeres MA, Guyatt G, Abel G, Alibhai S, Altman JK, Buckstein R, et al. American Society of Hematology  
531 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. *Blood Adv*.  
532 2020;4(15):3528-49.

- 533 9. Armenian S, Bhatia S. Predicting and Preventing Anthracycline-Related Cardiotoxicity. *Am Soc Clin Oncol*  
534 *Educ Book*. 2018;38:3-12.
- 535 10. Li Y, Tan M, Sun S, Stea E, Pang B. Targeted CRISPR activation and knockout screenings identify novel  
536 doxorubicin transporters. *Cell Oncol (Dordr)*. 2023.
- 537 11. Wlodek D, Banath J, Olive PL. Comparison between pulsed-field and constant-field gel electrophoresis for  
538 measurement of DNA double-strand breaks in irradiated Chinese hamster ovary cells. *International journal*  
539 *of radiation biology*. 1991;60(5):779-90.
- 540 12. van der Kant R, Fish A, Janssen L, Janssen H, Krom S, Ho N, et al. Late endosomal transport and tethering  
541 are coupled processes controlled by RILP and the cholesterol sensor ORP1L. *J Cell Sci*. 2013;126(Pt  
542 15):3462-74.
- 543 13. Schmidt D, Wilson MD, Spyrou C, Brown GD, Hadfield J, Odom DT. ChIP-seq: using high-throughput  
544 sequencing to discover protein-DNA interactions. *Methods*. 2009;48(3):240-8.
- 545 14. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods*. 2012;9(4):357-9.
- 546 15. Kharchenko PV, Tolstorukov MY, Park PJ. Design and analysis of ChIP-seq experiments for DNA-binding  
547 proteins. *Nat Biotechnol*. 2008;26(12):1351-9.
- 548 16. Amemiya HM, Kundaje A, Boyle AP. The ENCODE Blacklist: Identification of Problematic Regions of the  
549 Genome. *Scientific reports*. 2019;9(1):9354.
- 550 17. Roadmap Epigenomics C, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, et al. Integrative analysis  
551 of 111 reference human epigenomes. *Nature*. 2015;518(7539):317-30.
- 552 18. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, et al. Differential oestrogen  
553 receptor binding is associated with clinical outcome in breast cancer. *Nature*. 2012;481(7381):389-93.
- 554 19. Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. Transposition of native chromatin for fast  
555 and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. *Nat*  
556 *Methods*. 2013;10(12):1213-8.
- 557 20. Corces MR, Trevino AE, Hamilton EG, Greenside PG, Sinnott-Armstrong NA, Vesuna S, et al. An  
558 improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. *Nat*  
559 *Methods*. 2017;14(10):959-62.
- 560 21. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-  
561 Seq (MACS). *Genome biology*. 2008;9(9):R137.
- 562 22. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis  
563 predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest  
564 Oncology Group/Eastern Cooperative Oncology Group Study. *Blood*. 2000;96(13):4075-83.
- 565 23. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and  
566 management of acute myeloid leukemia in adults: recommendations from an international expert panel, on  
567 behalf of the European LeukemiaNet. *Blood*. 2010;115(3):453-74.
- 568 24. Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE. Plasma pharmacokinetics of adriamycin and  
569 adriamycinol: implications for the design of in vitro experiments and treatment protocols. *Cancer research*.  
570 1983;43(7):3417-21.
- 571 25. Kuo LJ, Yang LX. Gamma-H2AX - a novel biomarker for DNA double-strand breaks. *In vivo*.  
572 2008;22(3):305-9.

- 573 26. Cox J, Weinman S. Mechanisms of doxorubicin resistance in hepatocellular carcinoma. *Hepat Oncol.*  
574 2016;3(1):57-9.
- 575 27. Wang AH, Ughetto G, Quigley GJ, Rich A. Interactions between an anthracycline antibiotic and DNA:  
576 molecular structure of daunomycin complexed to d(CpGpTpApCpG) at 1.2-Å resolution. *Biochemistry.*  
577 1987;26(4):1152-63.
- 578 28. Gerstein MB, Kundaje A, Hariharan M, Landt SG, Yan KK, Cheng C, et al. Architecture of the human  
579 regulatory network derived from ENCODE data. *Nature.* 2012;489(7414):91-100.
- 580 29. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. High-resolution profiling of histone  
581 methylations in the human genome. *Cell.* 2007;129(4):823-37.
- 582 30. Alvarez F, Munoz F, Schilcher P, Imhof A, Almouzni G, Loyola A. Sequential establishment of marks on  
583 soluble histones H3 and H4. *The Journal of biological chemistry.* 2011;286(20):17714-21.
- 584 31. Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M, et al. Regulation of chromatin structure  
585 by site-specific histone H3 methyltransferases. *Nature.* 2000;406(6796):593-9.
- 586 32. Zhang M, Liang C, Chen Q, Yan H, Xu J, Zhao H, et al. Histone H2A phosphorylation recruits  
587 topoisomerase IIα to centromeres to safeguard genomic stability. *EMBO J.* 2020;39(3):e101863.
- 588 33. Kerpel-Fronius S, Gyergyay F, Hindy I, Decker A, Sawinsky I, Faller K, et al. Phase I-II trial of  
589 aclacinomycin A given in a four-consecutive-day schedule to patients with solid tumours. A South-East  
590 European Oncology Group (SEEOG) Study. *Oncology.* 1987;44(3):159-63.
- 591 34. Martino S, Decker DA, Hynes HE, Kresge CL. Phase II evaluation of aclacinomycin-A in advanced ovarian  
592 carcinoma. *Investigational new drugs.* 1987;5(4):373-4.
- 593 35. Johnson SA, Richardson DS. Anthracyclines in haematology: pharmacokinetics and clinical studies. *Blood*  
594 *Rev.* 1998;12(1):52-71.
- 595 36. Fujihira S, Yamamoto T, Matsumoto M, Yoshizawa K, Oishi Y, Fujii T, et al. The high incidence of atrial  
596 thrombosis in mice given doxorubicin. *Toxicol Pathol.* 1993;21(4):362-8.
- 597 37. Lencova-Popelova O, Jirkovsky E, Mazurova Y, Lenco J, Adamcova M, Simunek T, et al. Molecular  
598 remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-  
599 treatment follow up. *PLoS one.* 2014;9(5):e96055.
- 600 38. Zhao S, Wu H, Xia W, Chen X, Zhu S, Zhang S, et al. Periostin expression is upregulated and associated  
601 with myocardial fibrosis in human failing hearts. *J Cardiol.* 2014;63(5):373-8.
- 602 39. Guo R, Hua Y, Ren J, Bornfeldt KE, Nair S. Cardiomyocyte-specific disruption of Cathepsin K protects  
603 against doxorubicin-induced cardiotoxicity. *Cell Death Dis.* 2018;9(6):692.
- 604 40. Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, D'Ascenzo F, Malavasi V, et al. Review and meta-  
605 analysis of incidence and clinical predictors of anthracycline cardiotoxicity. *The American journal of*  
606 *cardiology.* 2013;112(12):1980-4.
- 607 41. Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, et al. Very poor long-term survival in past  
608 and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. *Am J Hematol.*  
609 2018;93(8):1074-81.
- 610 42. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management  
611 of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood.* 2017;129(4):424-  
612 47.



- 613 43. Yamada K, Furusawa S, Saito K, Waga K, Koike T, Arimura H, et al. Concurrent use of granulocyte  
614 colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute  
615 myelogenous leukemia: a pilot study. *Leukemia*. 1995;9(1):10-4.
- 616 44. Wei G, Ni W, Chiao JW, Cai Z, Huang H, Liu D. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF)  
617 regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.  
618 *Journal of hematology & oncology*. 2011;4:46.
- 619 45. Jin J, Chen J, Suo S, Qian W, Meng H, Mai W, et al. Low-dose cytarabine, aclarubicin and granulocyte  
620 colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy  
621 for older patients with acute myeloid leukemia. *Leuk Lymphoma*. 2015;56(6):1691-7.
- 622 46. Owattanapanich W, Owattanapanich N, Kungwankiatichai S, Ungprasert P, Ruchutrakool T. Efficacy and  
623 Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute  
624 Myeloid Leukemia: A Systematic Review and Meta-analysis. *Clin Lymphoma Myeloma Leuk*.  
625 2018;18(12):814-21 e3.
- 626 47. Wang H, Xiao X, Xiao Q, Lu Y, Wu Y. The efficacy and safety of daunorubicin versus idarubicin  
627 combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized  
628 clinical trials. *Medicine (Baltimore)*. 2020;99(24):e20094.
- 629 48. McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline Chemotherapy  
630 and Cardiotoxicity. *Cardiovasc Drugs Ther*. 2017;31(1):63-75.
- 631 49. DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of  
632 response and treatment failure after frontline venetoclax combinations in older patients with AML. *Blood*.  
633 2020;135(11):791-803.
- 634 50. Wu JF, Zhou JJ, Li XA, Hu LH, Wen ML. The safety and efficacy of amrubicin in the treatment of  
635 previously untreated extensive-disease small-cell lung cancer: a meta-analysis. *Onco Targets Ther*.  
636 2019;12:5135-42.
- 637 51. DiNardo S, Voelkel K, Sternglanz R. DNA topoisomerase II mutant of *Saccharomyces cerevisiae*:  
638 topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication.  
639 *Proceedings of the National Academy of Sciences of the United States of America*. 1984;81(9):2616-20.
- 640 52. Uemura T, Yanagida M. Isolation of type I and II DNA topoisomerase mutants from fission yeast: single  
641 and double mutants show different phenotypes in cell growth and chromatin organization. *EMBO J*.  
642 1984;3(8):1737-44.
- 643 53. Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K, Yanagida M. DNA topoisomerase II is required for  
644 condensation and separation of mitotic chromosomes in *S. pombe*. *Cell*. 1987;50(6):917-25.
- 645 54. Wander DPA, van der Zanden SY, Vriends MBL, van Veen BC, Vlaming JGC, Bruyning T, et al. Synthetic  
646 (N,N-Dimethyl)doxorubicin Glycosyl Diastereomers to Dissect Modes of Action of Anthracycline  
647 Anticancer Drugs. *The Journal of organic chemistry*. 2021;86(8):5757-70.
- 648 55. Holm C, Goto T, Wang JC, Botstein D. DNA topoisomerase II is required at the time of mitosis in yeast.  
649 *Cell*. 1985;41(2):553-63.
- 650 56. McPherson JP, Goldenberg GJ. Induction of apoptosis by deregulated expression of DNA topoisomerase  
651 II $\alpha$ . *Cancer research*. 1998;58(20):4519-24.

652 57. Seattle IHMaEI, United States. Global Burden of Disease Study 2019 Results. Global Burden of Disease  
653 Collaborative Network. 2020:Available from <https://vizhub.healthdata.org/gbd-results/>.

654

Clinical outcome	2 <sup>nd</sup> -line CAG (n=65)	2 <sup>nd</sup> -line Others (n=51)	P value	2 <sup>nd</sup> -line VA (n=31)	P value	1 <sup>st</sup> &2 <sup>nd</sup> -line CAG (n=17)	P value
Complete remission							
Overall	48/65 (74%)	19/51 (37%)	0.0001†	11/31 (35%)	0.0006†	10/17 (59%)	0.2433‡
Complete remission	0.0279‡		>0.9999‡		>0.9999‡		0.5500‡
Favourable and intermediate cytogenetics	40/50 (80%)	17/46 (37%)	<0.0001†	8/23 (35%)	0.0004†	8/13 (62%)	0.2704‡
Unfavourable cytogenetics	5/11 (45%)	2/5 (40%)	>0.9999†	2/5 (40%)	>0.9999†	1/3 (33%)	>0.9999†
Unknown cytogenetics	3/4 (75%)	0/0 (NA)	>0.9999†	1/2 (50%)	>0.9999†	1/1 (100%)	>0.9999†
Complete remission	0.0087‡		>0.9999‡		0.2553‡		>0.9999‡
Favourable and intermediate integrated risk	34/40 (85%)	12/32 (38%)	<0.0001†	5/19 (26%)	<0.0001†	6/10 (60%)	0.0966†
Unfavourable integrated risk	9/18 (50%)	6/16 (38%)	0.7055†	6/12 (50%)	>0.9999†	3/5 (60%)	>0.9999†
Unknown integrated risk	5/7 (71%)	1/3 (33%)	0.5000†	0/0 (NA)	>0.9999†	1/2 (50%)	>0.9999†

655

656 **Table 1. Treatment outcomes of r/rAML patients.** CAG: cytarabin, aclarubicin, G-CSF; IA: idarubicin,  
657 cytarabine; VA: venetoclax, azacitidine; Others: chemotherapy regimens other than CAG. Data are n/N (%). †  
658 Fisher's exact test between the indicated group and 2<sup>nd</sup>-line CAG group. ‡ Fisher's exact test within group.

659

660 **Figure 1. Acla differs from other anthracyclines in mechanisms of action and cross-resistance.** (A)  
661 Structures of anthracyclines used in this study. Chemical moieties divergent from Doxo are depicted in red. (B)  
662 DNA damage examined by  $\gamma$ H2AX Western blot. (C) Quantification of the  $\gamma$ H2AX signal normalized to  $\beta$ -  
663 actin. Data are mean  $\pm$  SEM;  $n = 4$  biological replicates; Student's *t*-test. (D) DSBs analyzed by CFGE. (E)  
664 Quantification of relative broken DNA in (D). Data are mean  $\pm$  SEM;  $n = 4$  biological replicates; Student's  
665 *t*-test. (F) Histone eviction revealed by cell fractionation assay in K562-eGFP-H2B cells. N, nuclear fraction; C,  
666 cytosolic fraction. Calnexin and Lamin B1 are the loading control of each fraction. (G) The distribution of  
667 eGFP-H2B was quantified for both compartments. Data are mean  $\pm$  SD;  $n = 4$  biological replicates; two-way  
668 ANOVA. (H) IC<sub>50</sub> of each anthracycline in different leukemia cell lines. (I, J) Cell viability of parental K562  
669 cells and ABCB1-overexpressing K562 cells upon Doxo (I) and Acla (J) treatment. Data are mean  $\pm$  SD;  
670  $n = 3$  biological replicates; two-way ANOVA. (K) Relative IC<sub>50</sub> folds of each condition compared to that of  
671 Doxo in parental K562 cells. Data are mean  $\pm$  SEM;  $n = 3$  biological replicates; Student's *t*-test. \**P* < 0.05,  
672 \*\**P* < 0.01, \*\*\**P* < 0.001, and \*\*\*\**P* < 0.0001; n.s., not significant.

673

674 **Figure 2. Epigenetic selectivity of TopoII $\alpha$  redistribution and histone eviction of anthracyclines.** (A)  
675 Illustration of drug-specific TopoII $\alpha$  redistribution revealed by ChIP-seq. (B) Principal component analysis  
676 (PCA) of TopoII $\alpha$  ChIP-seq data. Two independent biological replicates were included for each condition. (C)  
677 Heatmap of TopoII $\alpha$  peak abundance associated with specific histone features derived from Roadmap  
678 Epigenomics Project. (D) Illustration of drug-specific accessible chromatin regions revealed by ATAC-seq. (E)

679 PCA analysis of ATAC-seq data. Two independent biological replicates were included for each condition. (F)  
680 Heatmap of ATAC peak abundance associated with specific histone. (G) Density plots showing the accessible  
681 and inaccessible TopoII $\alpha$  regions, and TopoII $\alpha$ -excluded accessible regions surrounding  $\pm 2$  kb from the center  
682 of the detected peaks in the untreated K562 cells. (H) The abundance of each category in different conditions.

683


684 **Figure 3. Bio-distribution of clinically-used anthracyclines in mice.** (A) Drug bio-distribution was  
685 determined 4 hours after i.v. injection of indicated drug at 5 mg/kg. Data are represented as mean  $\pm$  SD from 5  
686 mice per group. Student's *t*-test. (B) Representative microscopic images of  $\gamma$ H2AX IHC staining of the hearts.  
687 Scale bars, 100  $\mu$ m. Quantification is represented as mean  $\pm$  SD,  $n = 5$ , Mann-Whitney test. \* $P < 0.05$ , \*\* $P <$   
688 0.01, \*\*\* $P < 0.001$ , and \*\*\*\* $P < 0.0001$ ; n.s., not significant.

689

690 **Figure 4. Acla is safe and well tolerated following Doxo treatment.** (A) Wild-type FVB mice were i.v.  
691 injected with Doxo (D), Acla (A), or saline (C) as indicated. (B-E) Representative microscopic images of the  
692 left atrium (LA) of heart. Lesions caused by Doxo treatment represent as impairment of the wall, thrombosis,  
693 inflammation, fibrosis/calcification, and disappearing of the lumen of atrium (filled by a large thrombus). Scale  
694 bars, 500  $\mu$ m. (F-H) Quantification of the indicated IHC staining in LA. Data are mean  $\pm$  SEM, Mann-  
695 Whitney test. (I) Animal survival is plotted in Kaplan-Meier curves. Log-rank test. (J) Cumulative incidence of  
696 cardiotoxicity. Fisher's exact test. (K) Incidence rate of cardiotoxicity. Two-way ANOVA with repeated  
697 measures, two-sided. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , and \*\*\*\* $P < 0.0001$ ; n.s., not significant.

698

699 **Figure 5. CAG is effective in treating r/rAML patients.** (A) The therapy overview of Ruijin AML cohort.  
700 CAG: cytarabin, aclarubicin, G-CSF; IA: idarubicin, cytarabine; VA: venetoclax, azacitidine; Others:  
701 chemotherapy regimens other than CAG. (B) Overall survival of the r/rAML patients from the start of r/rAML  
702 induction treatment to the date of death. Log-rank test. (C) The statistical analysis of OS of r/rAML patients at 2  
703 years. Data are n/N (%), \* compared with 2<sup>nd</sup>-line CAG group, † Fisher's exact test, ‡ Log-rank test, § Mantel-  
704 Haenszel test, # compared with 2<sup>nd</sup>-line CAG patients with favorable and intermediate cytogenetics. (D) Event-  
705 free survival of the r/rAML patients from the start of r/rAML induction treatment to the date of  
706 relapse/refractory/death. (E) The statistical analysis of EFS of r/rAML patients at 2 years. Data are n/N (%), \*  
707 compared with 2<sup>nd</sup>-line CAG group, † Fisher's exact test, ‡ Log-rank test, § Mantel-Haenszel test, # compared  
708 with 2<sup>nd</sup>-line CAG patients with favorable and intermediate cytogenetics.

**Figure 1**











**Figure 2****A****B****D****E****C****F****G****H**


Figure 3

**A**





**B**




**Figure 4**



**Figure 5****A****B****C**

OS of r/rAML at 2 years	2 <sup>nd</sup> -line CAG		2 <sup>nd</sup> -line Others		2 <sup>nd</sup> -line VA		1 <sup>st</sup> &2 <sup>nd</sup> -line CAG	
Overall	P value#		P value*		P value*		P value*	
Survival	36/63 (57%)		21/67 (31%)		17/33 (52%)		10/19 (53%)	
Median time (month)	NA		9.6		15.4		NA	
Hazard Ratio (95% CI)			2.109 (1.327 – 3.353)§		1.535 (0.7880 – 2.988)§		1.193 (0.5414 – 2.629)§	
Favourable and intermediate cytogenetics								
Survival	29/48 (60%)		17/58 (29%)		15/27 (56%)		7/14 (50%)	
Median time (month)	NA		9.2		NA		15.1	
Hazard Ratio (95% CI)			2.538 (1.522 – 4.232)§		1.521 (0.6995 – 3.306)§		1.474 (0.5683 – 3.822)§	
Unfavourable cytogenetics								
Survival	4/11 (36%)	0.1873†	3/7 (43%)	>0.9999†	1/5 (20%)	>0.9999†	1/3 (33%)	>0.9999†
Median time (month)	9.3	0.0698‡	10.2	0.7269‡	4.8	0.4112‡	5	0.6809‡
Hazard Ratio (95% CI)	2.758 (0.9213 – 8.255)§		0.8071 (0.2424 – 2.687)§		1.769 (0.4538 – 6.894)§		1.441 (0.2525 – 8.225)§	


**D****E**

EFS of r/rAML at 2 years	2 <sup>nd</sup> -line CAG		2 <sup>nd</sup> -line VA	
Overall	P value#		P value*	
Survival	29/63 (46%)		9/34 (26%)	
Median time (month)	15.2		3.35	
Hazard Ratio (95% CI)			2.121 (1.190 – 3.782)§	
Favourable and intermediate cytogenetics				
Survival	23/48 (48%)		8/27 (30%)	
Median time (month)	22.8		3.6	
Hazard Ratio (95% CI)			2.273 (1.161 – 4.449)§	
Unfavourable cytogenetics				
Survival	3/11 (27%)	0.3162†	1/5 (20%)	>0.9999†
Median time (month)	4.3	0.0684‡	1.7	0.7396‡
Hazard Ratio (95% CI)	2.543 (0.9318 – 6.942)§		1.212 (0.3493 – 4.207)§	


# Diverging the anthracycline class of anti-cancer drugs for superior survival of AML patients

## Anthracyclines


### Cross-resistance



### Histone eviction TopoII redistribution




### DNA double-strand break




### Aclarubicin


### Doxo-, Dauno-, Epi- & Idarubicin



Drug-specific epigenetic regulation



OS of r/rAML



Cardiotoxicity

Considering individual anthracyclines as different drugs can markedly improve survival of AML patients while reducing the toxic side-effects.